Newsroom

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Buffer UCITS ETF - April 21.08.2026 FAPR.LN IE000WX2HZQ7  250,002.00 USD   6,537,951.02   26.152  ...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) hat heute bekannt gegeben, dass die Europäische Kommission (EK) die Marktzulassung für DAYBU (Trofinetid) zur Behandlung neurobehavioraler Symptome des Rett-Syndroms bei Erwachsenen sowie pädiatrischen Patienten ab fünf Jahren erteilt hat. Damit ist DAYBU das erste und einzige Arzneimittel, das in der Europäischen Union (EU) für diese Indikation zugelassen ist. „Die Zulassung von DAYBU stellt einen wichtigen Meilenstein für...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) heeft vandaag aangekondigd dat de Europese Commissie (EC) een handelsvergunning heeft verleend voor DAYBU (trofinetide) voor de behandeling van neurologische gedragssymptomen van het Rett-syndroom bij volwassenen en pediatrische patiënten van vijf jaar en ouder, waarmee het de eerste en enige goedgekeurde behandeling is voor deze indicatie in de Europese Unie (EU). “De goedkeuring van DAYBU is een belangrijke stap voorwaarts...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) anunció hoy que la Comisión Europea (CE) ha concedido la autorización de comercialización de DAYBU (trofinetida) para el tratamiento de los síntomas neuroconductuales del síndrome de Rett en pacientes adultos y pediátricos de cinco años o más, lo que lo convierte en el primer y único tratamiento aprobado para el síndrome de Rett en la Unión Europea (UE). “La autorización de DAYBU marca un importante hito para la comunidad de...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and ad...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq : ACAD) a annoncé ce jour l’octroie par la Commission européenne (CE) de l’autorisation de mise sur le marché (AMM) de DAYBU (trofinetide) pour le traitement des symptômes neurocomportementaux du syndrome de Rett chez les patients adultes et pédiatriques âgés de cinq ans et plus, faisant de ce traitement le premier et unique approuvé par l’Union Européenne (UE) dans cette indication). « L’approbation de DAYBU représente une avancée...

TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) has appointed Ken Keller to the newly created role of Chief Commercialization Officer, responsible for accelerating further growth of the company’s oncology and specialty medicine business through a new globally integrated Commercialization Unit, effective April 1, 2027. As part of the operational excellence pillar outlined in the new Five-Year Business Plan of Daiichi Sankyo in May 2026, commercialization activities will be centralized and reo...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine o...

LOS ANGELES--(BUSINESS WIRE)--Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. The new capital will support the expansion of Own Network, Fasset’s regulated financial network that connects banks, telcos, payment and liqui...

BASEL, Switzerland & CHICAGO--(BUSINESS WIRE)--Camilla Corsi, Head of Crop Protection Research & Development at Syngenta, is the winner of the prestigious 2026 American Chemical Society (ACS) International Award for Research in Agrochemicals. The ACS Fall Meeting, starting today, will hold a symposium in her honor to recognize her influential leadership and contributions to the discovery of the fungicide pydiflumetofen (ADEPIDYN® technology); the insecticides isocycloseram (PLINAZOLIN® tech...